414:
market exclusivity; (2) utilize the internal review committee to review all written requests for pediatric studies issued; (3) track and make publicly available information on the pediatric studies conducted; (4) order the labeling of a product to include information about the results of the study and a statement that a pediatric study does or does not demonstrate that the drug is safe and effective in pediatric populations; and (5) ensure that all adverse event reports that have been received for a drug are referred to the Office of
Pediatric Therapeutics. It prescribes actions for the FDA to take if pediatric studies have not been completed and there is a continuing need for information relating to the use of the drug in the pediatric population.
38:
907:
455:
advisory committee. It prohibits any member of an advisory committee from participating with respect to any matter in which the member has a financial interest, unless the member is granted a waiver in order to afford the advisory committee essential expertise. The number of waivers is limited and decreases as a percentage of committee members over several years.
760:
442:
goals and priorities; (3) identify federal research and development programs and minimize duplication; (4) award grants to scientists and entities to efficiently and effectively advance such goals and priorities; and (5) provide objective clinical and scientific information to the FDA and other federal agencies.
534:
be published on the FDA's website, including documents related to the review of an application and a summary of conclusions from all reviewing disciplines about the drug. It stipulates that a scientific review of an application is considered the work of the reviewer and prohibits the altering of such
518:
It prohibits interstate commerce of any food that has an approved drug, licensed biological product, or certain other drugs or biological products added, unless the drug or biological product was marketed in food prior to approval, licensure, or clinical investigation, the FDA has approved the use of
492:
It requires a proposed risk evaluation and management strategy to include a timetable for assessment of the strategy and allows the FDA to require such a strategy to include additional elements, including distribution to each patient of a
Medication Guide and a patient package insert, a communication
445:
It requires the FDA to establish an Office of the Chief
Scientist to: (1) oversee, coordinate, and ensure quality and regulatory focus of FDA intramural research programs; (2) track and coordinate intramural research awards made by each FDA center or science-based office; (3) develop and advocate for
405:
to revise provisions regarding market exclusivity for pediatric drug studies on new or already approved drugs, including to change the definition of "pediatric studies" to authorize the
Secretary to include preclinical studies, to require the studies to be completed using appropriate formulations for
372:
It excludes a person granted a humanitarian device exemption from the prohibition against selling the device for an amount that exceeds its research and development, fabrication, and distribution costs if: (1) the device is intended to treat or diagnose a disease or condition that occurs in pediatric
300:
when applying for approval for a drug. Since then, it has been reauthorized three times; first in 1997, then 2002, and most recently with the passage of the FDAAA in 2007. The purpose of these fees is to provide resources to the FDA that help them more effectively review potential new drugs. The most
364:
It requires the FDA to submit an annual report to congressional committees that includes: (1) the number of devices approved in the preceding year for which there is a pediatric subpopulation that suffers from the disease; (2) the number of approved devices labeled for use in pediatric patients; (3)
342:
of "Medical Device User Fee
Amendments" (MDUFA). It defines terms relating to fees for medical devices. "30-day notice" is defined as a notice of a supplement to an approved application that is limited to a request to make modifications to manufacturing procedures or methods affecting the safety and
550:
It requires the FDA to work with states to assist in improving the safety of food. It requires a responsible person who determines that an article of food is a reportable food to submit a report to the FDA within 24 hours and to investigate the cause of the adulteration if the adulteration may have
471:
to require the FDA, acting through the
Director of NIH, to expand the clinical trials registry data bank. It requires the Director to ensure that the data bank is made publicly available through the Internet and requires the FDA to ensure that the data bank includes links to results information for
360:
Title III requires applications for a humanitarian device exemption, an application for premarket approval of a medical device, or a product development protocol for a medical device to include, if available, a description of any pediatric subpopulations that suffer from the disease that the device
546:
Title X requires the FDA to work with companies, professional associations, and other organizations during an ongoing recall of food regulated by the FDA to collect and aggregate information, to use existing networks to enhance the quality and speed of public communication, and to post information
441:
corporation to advance the mission of the FDA to modernize product development, accelerate innovation, and enhance product safety. It requires the
Foundation to: (1) identify unmet needs in the development, manufacture, and evaluation of the safety and effectiveness of such products; (2) establish
413:
It directs the FDA to: (1) publish a notice identifying any drug for which a pediatric formulation was developed, studied, and found to be safe and effective in the pediatric population if the pediatric formulation is not introduced onto the market within one year after the determination regarding
604:
program. This requires the FDA to award a transferable, priority review voucher to the sponsor of a tropical disease product application upon approval by the
Secretary of such application and establish a priority review user fee program. In this Act, only tropical diseases were covered under this
484:
It authorizes the FDA to require a responsible person for a drug to conduct a post-approval study or clinical trial of the drug to assess a known serious risk or signals of a serious risk or to identify an unexpected serious risk, to require a postapproval study or clinical trial for an already
454:
Title VII places limits on who can serve on an FDA advisory committee. It directs the FDA to implement strategies on effective outreach to potential members of advisory committees and to review the expertise and financial disclosure report of an individual when considering an appointment to an
385:
It requires that an applicant seeking waiver of pediatric assessment submission requirements on the grounds that a pediatric formulation cannot be developed, to submit documentation detailing why a pediatric formulation cannot be developed. It also authorizes the FDA to require submission of a
567:
Title XI requires the FDA to identify and periodically update clinically susceptible concentrations (specific values that characterize bacteria as clinically susceptible, intermediate, or resistant to the drug tested). It directs the FDA to convene a public meeting regarding which infectious
409:
It requires an applicant that does not agree to the request for a pediatric study to submit to the
Secretary the reasons such pediatric formulations cannot be developed, and requires an applicant that agrees to the request to provide the Secretary with all post-marketing adverse event reports
522:
It requires the FDA to develop standards to secure the drug supply chain against counterfeit, diverted, substandard, adulterated, misbranded, or expired drugs, to prioritize and develop standards for the identification and validation of prescription drugs, to develop a standardized numerical
381:
Title IV requires an applicant seeking to defer submission of some or all pediatric assessments of the safety and effectiveness of a new drug or biological product to submit to the FDA a timeline for the completion of pediatric studies. It also sets forth annual reporting requirements for an
373:
patients; (2) the device was not approved for pediatric patients prior to enactment of this Act; (3) the number of devices distributed does not exceed an annual distribution number specified by the
Secretary; and (4) the request for exemption is submitted on or before October 1, 2012.
446:
a budget to support intramural research; (4) develop a peer review process by which intramural research can be evaluated; (5) identify and solicit intramural research proposals from across the FDA; and (6) develop additional post-marketing safety performance measures.
48:
To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and for medical devices, to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs, and for other
503:
It authorizes the FDA to require the submission of any TV advertisement for a drug for review before it can be broadcast, to make recommendations with respect to information included in the label of the drug or on statements for inclusion in advertisements but not
526:
It requires the Advisory Committee on Risk Communication to regularly perform a comprehensive review of the types of risk information provided on the website and to recommend ways for the FDA to work with outside entities to help facilitate communication of risk.
519:
such drug or biological product in the food, or the use of the drug or the biological product is to enhance the safety or preservation of the food and not intended to have biological or therapeutic effects and the use is in conformity with specified regulations.
368:
It authorizes the FDA to determine that adult data on medical devices may be used to support claims of effectiveness in pediatric populations if the course of the disease and the effects of the device are sufficiently similar in adults and pediatric patients.
284:
to include post-marketing safety activities in the review of drug application. This included developing and using improved adverse event data collection systems and improved analytical tools to assess potential safety problems and conducting screenings of the
1160:
488:
It prohibits a person from introducing into interstate commerce a new drug or biological product for which a risk evaluation and mitigation strategy is required if the person fails to maintain compliance with the requirements of such strategy.
572:
or other incentives for development, and amends the Orphan Drug Act to reauthorize appropriations for grants and contracts to defray the costs of testing for the development of drugs, medical devices, and medical foods for rare diseases.
417:
It requires the pediatric subcommittee of the Oncologic Drugs Advisory Committee to provide recommendations to the internal review committee that reviews pediatric research requests with respect to the treatment of pediatric cancer.
485:
approved drug only if the Secretary becomes aware of new safety information, and to issue an order directing a responsible person or holder of an approved application to make a labeling change to address new safety information.
584:
that is contained in a racemic drug approved in another application to elect to have the single enantiomer considered the same active ingredient as that contained in the approved racemic drug under certain circumstances.
386:
pediatric assessment if the Secretary finds that adequate pediatric labeling could confer a benefit on pediatric patients or the absence of adequate pediatric labeling could pose a significant risk to pediatric patients.
558:
It requires the FDA to produce a report on any environmental risks associated with genetically engineered seafood products and sets forth reporting requirements with respect to food products regulated by the FDA.
480:
Title IX prohibits a "responsible person" from introducing into interstate commerce a new drug, if the person is in violation of a requirement related to post-approval clinical trials or labeling changes.
330:) from product and establishment fees if certain requirements are met, including that the drug is owned/licensed and marketed by a company having gross worldwide revenues that fall below a certain amount.
605:
program to incentivize the development of neglected tropical diseases. In 2012, this was expanded to include rare pediatric conditions. As of 2017, 13 priority review vouchers have been awarded.
592:
to conduct a study to assess the overall safety and quality of genetic tests and prepare a report that includes recommendations to improve federal oversight and regulation of genetic tests.
406:
each age group for which such a study is requested, and to prohibit the FDA from extending the period of market exclusivity later than nine months prior to the expiration of the period.
926:
829:
619:
346:
It makes changes to medical device fees, including establishing a fee for a 30-day notice, a request for classification information, and periodic reporting for a class III device.
349:
It extends the authority of accredited people (third parties) to review premarket reports for devices and make recommendations to the FDA regarding the classification of devices.
352:
It requires any establishment in a foreign country engaged in the manufacturing or processing of a drug or device that is imported into the US to annually register with the FDA.
188:
1209:
1199:
921:
896:
721:
425:
serves as the mechanism by which many studies on off-patent drugs are performed, in keeping with the BPCA objective of ensuring accurate drug labeling for children.
262:
The FDAAA extended the authority to levy fees to companies applying for approval of drugs, expanded clinical trial guidelines for pediatric drugs, and created the
861:
1145:
871:
856:
1155:
967:
508:
changes in such advertisements, and to require inclusion in advertisements of certain disclosures about a serious risk listed in the labeling of the drug.
886:
822:
251:
regulating the FDA. These changes allow the FDA to perform more comprehensive reviews of potential new drugs and devices. It was sponsored by Reps.
866:
472:
those clinical trials that form the primary basis of an efficacy claim or are conducted after the drug or device involved is approved or cleared.
313:
323:
drugs, including subjecting an applicant in a drug application for a PET drug to one-sixth of the annual prescription drug establishment fee.
1204:
815:
395:
931:
402:
281:
115:
991:
125:
936:
891:
614:
174:
96:
88:
1173:
941:
881:
293:
286:
275:
237:
1034:
538:
It directs the FDA to publish and update quarterly a complete list of all authorized generic drugs on the FDA's website.
1024:
838:
643:
320:
316:
to provide a partial refund of an applicant's user fees if the application is withdrawn without a waiver before filing.
143:
58:
876:
309:, and theoretically allow the FDA to more efficiently review and approve safe and effective new drugs for consumers.
1079:
702:
Research, Office of the Commissioner,Center for Biologics Evaluation and Research,Center for Drug Evaluation and.
1150:
1019:
497:
468:
37:
422:
306:
297:
677:
523:
identifier for prescription drugs, and to expand resources and facilities for securing the drug supply chain.
1009:
601:
434:
263:
946:
659:
660:"Cosponsors - H.R.3580 - 110th Congress (2007-2008): Food and Drug Administration Amendments Act of 2007"
1104:
589:
301:
recent reauthorization will further expand on the previous policy. It aims to broaden and upgrade the
247:(FDAAA) on September 27, 2007. This law reviewed, expanded, and reaffirmed several existing pieces of
81:
1059:
531:
17:
807:
1074:
551:
originated with the responsible person. It requires the FDA to immediately notify the Secretary of
1054:
1049:
464:
755:
166:
1194:
1039:
715:
552:
302:
365:
the number of fee-exempt devices approved; and (4) the review time for each approved device.
1109:
1084:
1044:
979:
555:
if the FDA believes food reported to the registry may have been deliberately adulterated.
1099:
1014:
569:
151:
797:
638:
296:. The PFUDA was first enacted in 1992 to allow the FDA to collect application fees from
1119:
1094:
1089:
1064:
1029:
240:
225:
197:
1188:
1129:
1114:
1069:
842:
764:
256:
1161:
Regulation of food and dietary supplements by the U.S. Food and Drug Administration
1124:
577:
327:
170:
802:
777:
512:
339:
326:
It exempts approved drugs or biological products designated for a rare disease (
248:
581:
252:
438:
568:
diseases potentially qualify for available grants and contracts under the
178:
100:
681:
356:
Title III: Pediatric Medical Device Safety and Improvement Act of 2007
511:
It requires the FDA to issue special guidance for clinical trials of
547:
regarding recalled food on the FDA's website in a single location.
476:
Title IX: Enhanced Authorities Regarding Postmarket Safety of Drugs
763:
This article incorporates text from this source, which is in the
703:
588:
It requires the HHS Secretary to enter into a contract with the
361:
is intended for, and the number of affected pediatric patients.
811:
206:
on September 20, 2007 (Unanimous Consent) with amendment
493:
plan to health care providers, and assurances of safe use.
212:
on September 20, 2007 (cleared) with further amendment
620:
Food and Drug Administration Safety and Innovation Act
390:
Title V: Best Pharmaceuticals for Children Act of 2007
270:
Title I: Prescription Drug User Fee Amendments of 2007
798:
https://www.fda.gov/oc/initiatives/advance/fdaaa.html
535:
work by management or the reviewer once it is final.
382:
applicant following the approval of such a deferral.
334:
Title II: Medical Device User Fee Amendments of 2007
189:
United States House Committee on Energy and Commerce
1138:
1002:
986:
974:
962:
955:
914:
849:
245:
Food and Drug Administration Amendments Act of 2007
149:
139:
131:
121:
111:
106:
87:
77:
72:
64:
53:
44:
31:
Food and Drug Administration Amendments Act of 2007
678:"BIO - The Prescription Drug User Fee Act (PDUFA)"
530:It requires that certain information related to a
312:It requires the FDA, through the authority of the
968:Title 21 of the Code of Federal Regulations (CFR)
922:Family Smoking Prevention and Tobacco Control Act
897:Office of Global Regulatory Operations and Policy
377:Title IV: Pediatric Research Equity Act of 2007
289:database and reporting on new safety concerns.
1146:Criticism of the Food and Drug Administration
823:
803:https://www.fda.gov/oc/initiatives/HR3580.pdf
8:
872:Center for Food Safety and Applied Nutrition
857:Center for Biologics Evaluation and Research
720:: CS1 maint: multiple names: authors list (
580:containing as an active ingredient a single
30:
1156:History of the Food and Drug Administration
992:Title 21 of the United States Code (U.S.C.)
959:
887:National Center for Toxicological Research
862:Center for Devices and Radiological Health
830:
816:
808:
437:for the Food and Drug Administration as a
778:"PRS Information: U.S. Public Law 110-85"
1210:Acts of the 110th United States Congress
1200:United States federal health legislation
704:"Prescription Drug User Fee Act (PDUFA)"
867:Center for Drug Evaluation and Research
630:
751:
713:
314:Secretary of Health and Human Services
259:and passed unanimously by the Senate.
29:
749:
747:
745:
743:
741:
739:
737:
735:
733:
731:
459:Title VIII: Clinical Trials Databases
396:Best Pharmaceuticals for Children Act
305:program, allocate more resources for
18:Best Pharmaceuticals for Children Act
7:
932:Federal Food, Drug, and Cosmetic Act
403:Federal Food, Drug, and Cosmetic Act
282:Federal Food, Drug, and Cosmetic Act
218:on September 20, 2007 (cleared)
658:John, Dingell (27 September 2007).
165:in the House of Representatives as
116:Federal Food, Drug and Cosmetic Act
25:
892:Office of Criminal Investigations
615:U.S. Food and Drug Administration
576:It allows an applicant for a non-
429:Title VI: Reagan-Udall Foundation
905:
758:
450:Title VII: Conflicts of Interest
319:It sets forth special rules for
216:Senate agreed to House amendment
210:House agreed to Senate amendment
36:
596:Priority review voucher program
1174:Commissioner of Food and Drugs
956:Title 21 regulations and rules
942:Prescription Drug User Fee Act
882:Center for Veterinary Medicine
294:Prescription Drug User Fee Act
287:Adverse Event Reporting System
276:Prescription Drug User Fee Act
266:program, amongst other items.
238:President of the United States
1:
937:Food Safety Modernization Act
394:Title V has the short title "
343:effectiveness of the device.
1205:Food and Drug Administration
839:Food and Drug Administration
644:Food and Drug Administration
321:positron emission tomography
196:on September 19, 2007 (
144:Food and Drug Administration
59:110th United States Congress
877:Center for Tobacco Products
498:Drug Safety Oversight Board
463:Title VIII is in regard to
1226:
782:prsinfo.clinicaltrials.gov
600:Title XI also created the
563:Title XI: Other Provisions
273:
1169:
1151:FDA Most Wanted Fugitives
927:Modernization Act of 1997
903:
469:Public Health Service Act
433:Title VI establishes the
292:It also reauthorizes the
158:
126:21 U.S.C.: Food and Drugs
35:
423:Pediatric Trials Network
298:pharmaceutical companies
602:priority review voucher
435:Reagan-Udall Foundation
264:priority review voucher
185:Committee consideration
181:) on September 19, 2007
132:U.S.C. sections amended
947:Pure Food and Drug Act
338:Title II is given the
307:television advertising
1105:Andrew von Eschenbach
980:Federal Register (FR)
639:"Law Strengthens FDA"
590:Institute of Medicine
228:on September 27, 2007
1060:Alexander M. Schmidt
542:Title X: Food Safety
532:new drug application
410:regarding the drug.
1139:Society and culture
1075:Arthur H. Hayes Jr.
1035:Charles W. Crawford
496:It establishes the
280:Title I amends the
152:Legislative history
32:
1055:Charles C. Edwards
1025:Walter G. Campbell
963:Administrative law
465:clinicaltrials.gov
68:September 27, 2007
1182:
1181:
1040:George P. Larrick
1020:Charles A. Browne
998:
997:
553:Homeland Security
235:
234:
204:Passed the Senate
140:Agencies affected
90:Statutes at Large
16:(Redirected from
1217:
1110:Margaret Hamburg
1085:David A. Kessler
1045:James L. Goddard
960:
909:
908:
832:
825:
818:
809:
786:
785:
774:
768:
762:
761:
753:
726:
725:
719:
711:
699:
693:
692:
690:
689:
680:. Archived from
674:
668:
667:
664:www.congress.gov
655:
649:
648:
635:
467:. It amends the
194:Passed the House
154:
91:
40:
33:
21:
1225:
1224:
1220:
1219:
1218:
1216:
1215:
1214:
1185:
1184:
1183:
1178:
1165:
1134:
1100:Lester Crawford
1015:Carl L. Alsberg
1010:Harvey W. Wiley
994:
982:
975:Federal journal
970:
951:
910:
906:
901:
845:
836:
794:
789:
776:
775:
771:
759:
754:
729:
712:
701:
700:
696:
687:
685:
676:
675:
671:
657:
656:
652:
637:
636:
632:
628:
611:
598:
570:Orphan Drug Act
565:
544:
478:
461:
452:
431:
392:
379:
358:
336:
278:
272:
231:
222:Signed into law
150:
89:
54:Enacted by
28:
23:
22:
15:
12:
11:
5:
1223:
1221:
1213:
1212:
1207:
1202:
1197:
1187:
1186:
1180:
1179:
1177:
1176:
1170:
1167:
1166:
1164:
1163:
1158:
1153:
1148:
1142:
1140:
1136:
1135:
1133:
1132:
1127:
1122:
1120:Scott Gottlieb
1117:
1112:
1107:
1102:
1097:
1095:Mark McClellan
1092:
1090:Jane E. Henney
1087:
1082:
1080:Frank E. Young
1077:
1072:
1067:
1065:Donald Kennedy
1062:
1057:
1052:
1050:Herbert L. Ley
1047:
1042:
1037:
1032:
1030:Paul B. Dunbar
1027:
1022:
1017:
1012:
1006:
1004:
1000:
999:
996:
995:
990:
988:
984:
983:
978:
976:
972:
971:
966:
964:
957:
953:
952:
950:
949:
944:
939:
934:
929:
924:
918:
916:
912:
911:
904:
902:
900:
899:
894:
889:
884:
879:
874:
869:
864:
859:
853:
851:
847:
846:
837:
835:
834:
827:
820:
812:
806:
805:
800:
793:
792:External links
790:
788:
787:
769:
756:H.R. 3580
727:
694:
669:
650:
629:
627:
624:
623:
622:
617:
610:
607:
597:
594:
564:
561:
543:
540:
477:
474:
460:
457:
451:
448:
430:
427:
401:It amends the
391:
388:
378:
375:
357:
354:
335:
332:
274:Main article:
271:
268:
241:George W. Bush
233:
232:
230:
229:
226:George W. Bush
219:
213:
207:
201:
191:
182:
167:H.R. 3580
159:
156:
155:
147:
146:
141:
137:
136:
133:
129:
128:
123:
122:Titles amended
119:
118:
113:
109:
108:
104:
103:
93:
85:
84:
79:
75:
74:
70:
69:
66:
62:
61:
55:
51:
50:
46:
42:
41:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
1222:
1211:
1208:
1206:
1203:
1201:
1198:
1196:
1193:
1192:
1190:
1175:
1172:
1171:
1168:
1162:
1159:
1157:
1154:
1152:
1149:
1147:
1144:
1143:
1141:
1137:
1131:
1130:Robert Califf
1128:
1126:
1123:
1121:
1118:
1116:
1115:Robert Califf
1113:
1111:
1108:
1106:
1103:
1101:
1098:
1096:
1093:
1091:
1088:
1086:
1083:
1081:
1078:
1076:
1073:
1071:
1070:Jere E. Goyan
1068:
1066:
1063:
1061:
1058:
1056:
1053:
1051:
1048:
1046:
1043:
1041:
1038:
1036:
1033:
1031:
1028:
1026:
1023:
1021:
1018:
1016:
1013:
1011:
1008:
1007:
1005:
1003:Commissioners
1001:
993:
989:
985:
981:
977:
973:
969:
965:
961:
958:
954:
948:
945:
943:
940:
938:
935:
933:
930:
928:
925:
923:
920:
919:
917:
913:
898:
895:
893:
890:
888:
885:
883:
880:
878:
875:
873:
870:
868:
865:
863:
860:
858:
855:
854:
852:
848:
844:
843:United States
840:
833:
828:
826:
821:
819:
814:
813:
810:
804:
801:
799:
796:
795:
791:
783:
779:
773:
770:
766:
765:public domain
757:
752:
750:
748:
746:
744:
742:
740:
738:
736:
734:
732:
728:
723:
717:
709:
705:
698:
695:
684:on 2008-03-07
683:
679:
673:
670:
665:
661:
654:
651:
646:
645:
640:
634:
631:
625:
621:
618:
616:
613:
612:
608:
606:
603:
595:
593:
591:
586:
583:
579:
574:
571:
562:
560:
556:
554:
548:
541:
539:
536:
533:
528:
524:
520:
516:
514:
509:
507:
501:
499:
494:
490:
486:
482:
475:
473:
470:
466:
458:
456:
449:
447:
443:
440:
436:
428:
426:
424:
419:
415:
411:
407:
404:
399:
397:
389:
387:
383:
376:
374:
370:
366:
362:
355:
353:
350:
347:
344:
341:
333:
331:
329:
324:
322:
317:
315:
310:
308:
304:
299:
295:
290:
288:
283:
277:
269:
267:
265:
260:
258:
257:Frank Pallone
254:
250:
246:
242:
239:
227:
224:by President
223:
220:
217:
214:
211:
208:
205:
202:
199:
195:
192:
190:
186:
183:
180:
176:
172:
168:
164:
161:
160:
157:
153:
148:
145:
142:
138:
134:
130:
127:
124:
120:
117:
114:
110:
105:
102:
98:
94:
92:
86:
83:
80:
76:
71:
67:
63:
60:
56:
52:
47:
43:
39:
34:
19:
1125:Stephen Hahn
781:
772:
707:
697:
686:. Retrieved
682:the original
672:
663:
653:
642:
633:
599:
587:
578:racemic drug
575:
566:
557:
549:
545:
537:
529:
525:
521:
517:
510:
505:
502:
495:
491:
487:
483:
479:
462:
453:
444:
432:
420:
416:
412:
408:
400:
393:
384:
380:
371:
367:
363:
359:
351:
348:
345:
337:
328:orphan drugs
325:
318:
311:
291:
279:
261:
244:
236:
221:
215:
209:
203:
193:
184:
171:John Dingell
162:
112:Acts amended
107:Codification
987:Federal law
708:www.fda.gov
513:antibiotics
340:short title
303:drug safety
249:legislation
243:signed the
1189:Categories
915:Major acts
688:2008-03-19
626:References
582:enantiomer
253:Joe Barton
163:Introduced
78:Public law
45:Long title
850:Divisions
439:nonprofit
95:121
73:Citations
65:Effective
49:purposes.
1195:Food law
716:cite web
609:See also
841:of the
506:require
99:
82:110-85
27:US law
198:405-7
97:Stat.
722:link
421:The
398:".
255:and
57:the
515:.
187:by
169:by
135:301
101:823
1191::
780:.
730:^
718:}}
714:{{
706:.
662:.
641:.
500:.
179:MI
831:e
824:t
817:v
784:.
767:.
724:)
710:.
691:.
666:.
647:.
200:)
177:–
175:D
173:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
